Last reviewed · How we verify
AZD4573
At a glance
| Generic name | AZD4573 |
|---|---|
| Also known as | AZ13810325 |
| Sponsor | AstraZeneca |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer (PHASE1, PHASE2)
- AZD4573 as Monotherapy or in Combinations With Anti-cancer Agents in Patients With r/r PTCL or r/r cHL (PHASE2)
- Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AZD4573 CI brief — competitive landscape report
- AZD4573 updates RSS · CI watch RSS
- AstraZeneca portfolio CI